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Introduction
Coronary artery disease (CAD) is a major cause of mor-
bidity and mortality in patients with diabetes.1 Guidelines 
therefore recommend management of cardiovascular risk 
factors, including lifestyle interventions and treatment 
with statins, anti-hypertensive agents, specific glucose-
lowering medications and consideration of antiplatelet 
therapy in high- and very high-risk diabetic patients.1,2
Haffner et al.3 reported that diabetes patients without 
prior myocardial infarction (MI) had a risk of MI similar to 
non-diabetes patients with previous MI. Subsequent stud-
ies, however, demonstrated that the impact of diabetes on 
a future MI was probably overestimated in the study by 
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Haffner et al,3 but remained higher than observed in non-
diabetes comparison groups.4,5 We have recently reported 
that diabetes patients had the same risk of MI as non-diabetes 
patients in the absence of obstructive CAD ascertained by 
either coronary angiography (CAG) or coronary computed 
tomography angiography (CCTA).6,7 However, these stud-
ies were limited by moderate follow-up periods (median of 
4.1 years in the CAG study), lack of knowledge concerning 
diabetes type, diabetes duration and potential impact of cor-
onary revascularization. In this updated cohort, we have 
included these data and have extended follow-up to 11 years. 
Our main objective was to examine whether the risk of MI 
remained similar in diabetes and non-diabetes patients in the 
absence of angiographically significant CAD.
Methods
Data sources
Each Danish resident is allocated a unique and permanent 
10-digit personal identifier at birth or upon immigration. 
This identifier is used in every Danish health registry and 
facilitates accurate long-term follow-up data with minimal 
risk of loss to follow-up. The Western Denmark Heart 
Registry (WDHR) is a clinical database covering data on 
all patients referred for diagnostic, invasive and cardiac 
procedures in Western Denmark since 1999 (approxi-
mately 3.3 million inhabitants).8,9 The WDHR contains 
information on patient and procedural characteristics, 
including >240,000 CAGs with detailed description of the 
presence and extent of CAD. Besides the WDHR, we used 
the following databases: the Danish Civil Registration 
System, which records data on all Danish residents’ vital 
status (dead, alive, or emigrated); the Danish National 
Patient Registry, which collects data on all inpatient and 
outpatient hospital diagnoses and procedure codes; the 
Danish Register of Causes of Death, which collects causes 
of death of all Danish residents; and the Danish National 
Prescription Registry, which provides data on all reim-
bursed prescriptions redeemed at Danish pharmacies since 
1994.10–14
CAD
CAD status was ascertained from the WDHR. CAD was 
defined as obstructive CAD, that is, ⩾1 coronary artery 
with ⩾50% angiographic lumen narrowing or as diffuse 
CAD, that is, <50% stenosis in >1 coronary artery. No 
CAD was defined as no stenosis in all coronary arteries 
or mild angiographic lumen narrowing (<50%) in a sin-
gle coronary artery.
Diabetes
Diabetes patients were identified as follows: insulin 
± oral diabetes treatment, oral diabetes treatment, or 
non-pharmacological dietary treated diabetes at the time of 
CAG as registered in the WDHR; redemption of ⩾1 
prescription(s) for diabetes medication within 6 months 
before and 1 month after CAG; and/or a diagnosis of dia-
betes registered in the Danish National Registry prior to 
CAG. Diabetes duration was classified according to date 
of first redemption of diabetes medication as recorded in 
the Danish National Prescription Registry (and thus per 
definition not available for non-pharmacological dietary 
treated diabetes). Since the Danish National Prescription 
Registry was established in 1994 and patients were 
included from 2003, we chose to classify diabetes duration 
in categories of <5, 5−10 and >10 years. Type 1 diabetes 
patients were defined as patients redeeming an insulin pre-
scription within 6 months before and 1 month after CAG 
and no history of redemption of non-insulin diabetes pre-
scription. Type 2 diabetes patients were defined as patients 
redeeming a non-insulin diabetes prescription ± insulin 
treatment within 6 months before and 1 month after CAG 
or as patients registered in the WDHR with non-pharmaco-
logical dietary treated diabetes. Anatomical Therapeutic 
Chemical (ATC) codes for diabetes medications are pro-
vided in the Supplemental Table S1.
Patient selection
All patients with a CAG registered in the WDHR between 
1 January 2003 and 31 December 2012 were included in 
the study (Figure 1). For patients undergoing >1 CAG 
during the study period, the first CAG was used as the 
index procedure. Patients aged <18 years and patients 
Figure 1. Flowchart of patients undergoing coronary 
angiography in Western Denmark between 1 January 2003 and 
31 December 2012.
CABG: coronary artery bypass grafting; CAD: coronary artery disease; 
CAG: coronary angiography; DM: diabetes mellitus; MI: myocardial 
infarction; PCI: percutaneous coronary intervention.
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with missing CAD status were excluded. To reduce the 
risk of CAD misclassification, we excluded all patients 
with a previous MI, percutaneous coronary intervention 
(PCI) and/or coronary artery bypass grafting. Patients with 
<30 days of follow-up also were excluded.
Medication
Records of treatment with insulin, non-insulin diabetes 
medications, statins, β-blockers, angiotensin-converting 
enzyme (ACE) inhibitors, angiotensin II receptor blockers 
(ARB), calcium channel blockers, thiazide diuretics, aspi-
rin, adenosine diphosphate (ADP) receptor inhibitors, vita-
min K antagonists (VKA) and non-vitamin K oral 
anticoagulants (NOAC) were obtained from the Danish 
National Prescription Registry (Supplemental Table S1).14 
Medical treatment was defined as reimbursement of a 
redeemed prescription between 6 months before and 1 
month after the date of the index CAG.
MI
MI diagnoses were obtained from the Danish National 
Patient Registry using the diagnosis codes provided in 
Supplemental Table S2.11,12
Cardiac death
Cardiac death was defined as death caused by ischemic 
heart disease, cardiac arrest with unspecified cause, ven-
tricular tachycardia or other specified cardiac arrhythmias, 
heart failure, sudden death with unspecified cause or unat-
tended death with unspecified cause, as recorded on death 
certificates from the Danish Register of Causes of Death 
(Supplemental Table S3).13
All-cause death
Patients’ vital status (dead, alive or emigrated) was pro-
vided from the Danish Civil Registration System.10
Coronary revascularization
Coronary revascularization was ascertained from the 
Danish National Patient Registry and was defined as any 
PCI or coronary artery bypass grafting procedure >90 days 
after the index CAG. Follow-up began 90 days after the 
index CAG to exclude coronary revascularizations per-
formed as a result of the CAG findings.
Comorbidity
Comorbidities were evaluated using a modified Charlson 
comorbidity index score (excluding ‘diabetes’ and ‘dia-
betes with end-organ damage’) based on International 
Classification of Diseases (ICD)-10 codes registered in 
the Danish National Patient Registry (Supplemental 
Table S2).15 We used a full look-back period of patient 
history before the date of the index CAG.
Statistical analyses Follow-up began 30 days after the 
index CAG except for patients undergoing coronary revas-
cularization, for whom follow-up began 90 days after 
CAG, and continued until death, emigration or end of fol-
low-up (31 December 2018), whichever occurred first. We 
estimated event rates for each endpoint per 100 person-
years and constructed cumulative incidence proportion 
curves corresponding to the 75th percentile of follow-up. 
Cumulative incidence proportions of MI, cardiac death 
and coronary revascularization were estimated accounting 
for the competing risk of death.16 We used Cox propor-
tional hazard regression to estimate unadjusted and 
adjusted hazard ratios (HRs) of MI, cardiac death, and all-
cause death, using patients with neither CAD nor diabetes 
as reference. The assumption of proportional hazards 
(examined by log-log plot) was not met for coronary revas-
cularization. Therefore, we used modified Poisson regres-
sion, with the event as the outcome and the natural log of 
person-years as the offset, to estimate unadjusted and 
adjusted incidence rate ratios (IRRs) of coronary revascu-
larization.17 Each endpoint was adjusted for age, sex, 
hypertension, active smoking, previous ischemic stroke, 
previous peripheral artery disease (PAD), procedural pri-
ority (acute, subacute or elective CAG), year of index 
CAG, statin treatment, oral anticoagulant treatment (VKA 
and/or NOAC), and antiplatelet treatment (aspirin and/or 
ADP receptor inhibitor). For coronary revascularization, 
we further adjusted for coronary revascularization 
<90 days after CAG. When calculating HRs and IRRs, the 
maximum follow-up time was 11 years. We used multiple 
imputations with chained equations to impute missing val-
ues for smoking status generating 11 imputed data sets 
(11% missing values). We performed subgroup analyses 
limited to either patients with type 1 diabetes (n = 1259) or 
patients with type 2 diabetes (n = 11,393) provided in 
Supplemental Tables S4 and S5, respectively. We also per-
formed subgroup analyses restricted to male patients 
(Supplemental Table S6) or female patients (Supplemental 
Table S7). We tested for interaction between sex and dia-
betes/CAD status. p < 0.05 was considered significant. 
Stata/MP software version 15.1 (StataCorp, College 
Station, Texas, USA) was used for all statistical analyses. 
The study was approved by the Danish Data Protection 
Agency (record no. 1-16-02-193-18).
Results
A total of 86,202 patients were included in the study 
(Figure 1). Of these, 31,116 (36.1%) patients had neither 
CAD nor diabetes, 4068 (4.7%) had diabetes alone, 42,434 
(49.2%) had CAD alone, and 8584 (10.0%) had both CAD 
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and diabetes. Median follow-up time was 8.8 years (Q1−Q3: 
6.6−11.5). Two patients were lost during follow-up and 
368 patients emigrated during follow-up and were cen-
sored from that date.
Baseline characteristics
Patients with CAD were older, more often male, and were 
characterized by higher proportions of active smoking, 
peripheral artery disease, and treatment with statins, β-blockers, 
aspirin and ADP inhibitors (Table 1). Furthermore, patients 
with CAD were more likely to undergo acute CAG.
Patients with diabetes more frequently had hyperten-
sion, heart failure, previous ischemic stroke, and were 
more often treated with ACE inhibitors, ARBs, calcium 
channel blockers, and thiazide diuretics. Diabetes medica-
tion use was similar in diabetes patients with and without 
CAD and metformin treatment was the most frequently 
used diabetes medication. Distribution of diabetes type 
was similar in diabetes patients with and without CAD, 
with approximately 90% of patients having type 2 diabe-
tes. Diabetes duration was longer in patients with CAD.
Clinical endpoints
During the follow-up period, 5935 patients had a MI, 
23,436 patients died (4455 from cardiac causes) and 9530 
patients underwent coronary revascularization (Table 2). 
Cumulative incidence curves for each endpoint are shown 
in Figure 2(a)–(d).
Event rates for MI, cardiac death, all-cause death, and 
coronary revascularization were lowest in patients with 
neither CAD nor diabetes, followed by patients with dia-
betes alone, patients with CAD alone, and highest in 
patients with both CAD and diabetes (Table 2). Using 
patients with neither CAD nor diabetes as reference 
(cumulative MI incidence 2.6%), the risk of MI was low 
and not substantially increased in patients with diabetes 
alone (3.2%; HR 1.202, 95% CI 0.996−1.451), increased 
in patients with CAD alone (9.3%; HR 2.75, 95% CI 
2.52−3.01) and further increased in patients with both 
CAD and diabetes (12.3%; HR 3.79, 95% CI 3.43−4.20). 
Similar associations were observed for cardiac death and 
coronary revascularization, although the risk was signifi-
cantly increased in patients with diabetes alone compared 
to patients with neither CAD nor diabetes (Table 2). Still, 
the absolute risk of cardiac death and coronary revasculari-
zation remained low in patients without CAD regardless of 
diabetes status compared to patients with CAD alone and 
patients with both CAD and diabetes. For all-cause death, 
the risk was lowest in patients with neither CAD nor dia-
betes (reference), followed by patients with CAD alone 
(HR 1.35, 95% CI 1.30−1.40), patients with diabetes alone 
(HR 1.67, 95% CI 1.57−1.78), and highest in patients with 
both CAD and diabetes (HR 2.17, 95% CI 2.08−2.28).
The results were robust when stratified for type of dia-
betes (Tables S4 S5) or sex (Tables S6 S7). We did not see 
any interaction between sex and status of diabetes/CAD 
for MI (p = 0.71). There was no interaction with sex among 
diabetes patients without CAD either (p = 0.35).
Discussion
In this study, we extend our previous shorter term assess-
ments demonstrating that diabetes patients without CAD 
by CAG or CCTA have a low risk of MI, not substan-
tially increased compared to patients with neither CAD 
nor diabetes.6,7 In the current evaluation with prolonged 
follow-up, we found that diabetes patients, commonly 
believed to have an increased risk of MI due to acceler-
ated atherosclerosis, remained at low risk of MI for at 
least an 11 year period if they had no or mild CAD at the 
baseline evaluation. Diabetes patients with CAD, how-
ever, continued to have a much higher risk than patients 
with CAD alone. Thus, a single imaging assessment of 
the coronary arteries provides risk stratification that 
extends out to 11-year follow-up, even in an assumed 
high-risk diabetes population.
Our previous CAG study, based on the same patient 
cohort, was limited to a maximum follow-up of 7 years and 
the database did not include data on diabetes type, diabetes 
duration, and coronary revascularization following CAG.6 
In this updated cohort, we have included such data and 
have extended our follow-up to 11 years, corresponding to 
the 75th percentile of follow-up. Approximately 90% of 
diabetes patients had type 2 diabetes, irrespective of CAD 
status. When we restricted our analyses to patients with 
either type 1 or type 2 diabetes, the results did not change. 
However, we found that diabetes duration was longer in 
diabetes patients with CAD than without CAD, also 
reflecting older age among the former. The Framingham 
Heart Study also demonstrated that long diabetes duration 
was associated with increased risk of CAD and cardiac 
death, independently of other coexisting risk factors.18 Our 
data further revealed the important distinction that very 
few diabetes patients without CAD develop significant 
CAD, as determined by MI event or coronary revasculari-
zation, during an 11-year follow-up.
In this study, the risk of MI between patients with dia-
betes alone versus those with neither diabetes nor CAD 
was borderline significant, that is, the 95% CI varied from 
0.4% lower relative risk to a potential 45% increased rela-
tive risk. However, the absolute risk difference between 
diabetes alone and the reference group was 0.60% during 
the 11-year follow-up. This corresponds to an absolute risk 
increase in 0.05% per year, which is not considered clini-
cally relevant. In comparison, the absolute risk difference 
was 7% when compared to patients with CAD alone and 
10% when compared to patients with both CAD and 
diabetes.
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Table 1. Baseline patient characteristics.
−CAD −DM 
(n = 31,116)
−CAD +DM 
(n = 4068)
+CAD −DM 
(n = 42,434)
+CAD +DM 
(n = 8584)
Male (%) 49.2 51.3 69.8 69.4
Median age (years) (IQR) 60 (51–68) 61 (53–69) 66 (58–74) 67 (59–74)
Median follow-up (years) (IQR) 9.4 (7.1–11.9) 8.4 (6.4–11.0) 8.7 (6.5–11.3) 7.7 (5.3–10.3)
Active smoker (%)a 22.7 20.3 32.5 25.8
Median body mass index (kg/m2) (IQR) 26 (23–29) 30 (26–35) 26 (24–29) 29 (25–32)
Type 2 DM (%) – 90.9 – 89.7
DM durationb
 0–5 years (%) – 59.1 – 52.2
 5–10 years (%) – 20.0 – 20.5
 >10 years (%) – 20.9 – 27.3
Cardiovascular comorbidity
Hypertension (%) 47.4 76.6 53.9 79.0
Previous heart failure (%) 11.8 16.6 12.0 17.5
Previous ischemic stroke (%) 1.3 3.3 2.0 4.2
Previous peripheral artery disease (%) 2.2 3.6 5.1 10.5
Medical treatment
Insulin (%) – 29.5 – 33.0
Non-insulin diabetes medication – 60.1 – 61.2
 Metformin (%) – 50.0 – 48.1
 Sulfonylurea (%) – 23.4 – 28.7
 GLP-1 analogue (%) – 2.5 – 1.9
 DPP-4 inhibitor (%) – 3.4 – 3.2
 Glitazone (%) – 1.0 – 1.3
Statin (%) 43.1 72.1 86.3 88.0
β-blocker (%) 51.4 56.3 76.3 73.7
ACE inhibitor (%) 28.2 47.1 37.1 54.3
ARB (%) 12.8 28.8 14.1 28.8
Calcium channel blocker (%) 24.5 35.2 28.6 40.6
Thiazide diuretic (%) 17.0 22.3 17.5 22.7
Aspirin (%) 54.9 67.2 86.1 85.7
ADP receptor inhibitor (%) 5.3 5.0 57.9 47.4
VKA (%) 13.7 15.5 9.1 11.5
NOAC (%) 0.3 0.4 0.3 0.3
Modified Charlson comorbidity index score
0 (%) 75.0 71.9 76.6 74.4
1 (%) 15.6 19.0 13.3 16.7
2 (%) 6.4 8.1 6.6 7.8
≥ 3 (%) 3.1 1.0 3.5 1.1
Procedural priority
Elective/subacute (%) 92.5 94.4 72.2 82.9
Acute (%) 7.5 5.6 27.8 17.1
Procedural indication
STEMI (%) 4.3 3.0 25.7 15.0
NSTEMI (%) 8.1 7.1 18.4 18.0
Unstable AP (%) 2.1 2.0 1.9 2.1
Stable AP (%) 44.7 48.4 36.9 43.7
Valvular disease (%) 12.3 10.3 5.8 6.8
Cardiomyopathy (%) 8.5 9.4 3.1 5.5
Other (%) 20.0 19.8 8.2 8.9
ACE: angiotensin-converting enzyme; AP: angina pectoris; ARB: angiotensin-II receptor blocker; CAD: coronary artery disease; DM: diabetes 
mellitus; DPP-4 inhibitor: dipeptidyl peptidase-4 inhibitor; GLP-1 analogue: glucagon-like peptide-1 analogue; IQR: interquartile range; NOAC: non-
vitamin K oral anticoagulant; NSTEMI: non-ST-elevation myocardial infarction; STEMI: ST-elevation myocardial infarction; VKA: vitamin K antagonist.
a11% missing values for smoking.
b11% missing values for DM duration.
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We observed an increased risk of all-cause death in 
patients with diabetes alone compared to patients with nei-
ther CAD nor diabetes, which is not explained by increased 
risk of cardiac death alone. Beyond cardiac disease, diabe-
tes is associated with other macrovascular complications 
such as stroke and peripheral artery disease. Hence, we 
have previously reported that diabetes patients without 
CAD had increased risk of ischemic stroke compared to 
patients with neither CAD nor diabetes (adjusted IRR 
1.74, 95% CI, 1.42–2.15), although the risk was lower risk 
than in patients with CAD and diabetes combined.19 In 
addition, diabetes also adversely affects the microvascula-
ture in multiple organs leading to complications such as 
kidney failure and peripheral neuropathy.20 Thus, the 
absence of CAD by CAG ensures an 11-year low risk of 
MI for diabetes patients, but it only provides moderate 
protection against macrovascular complications, such as 
stroke19 and possibly PAD, which could explain the 
observed increased mortality in diabetes patients. 
Furthermore, microvascular complications, particularly 
kidney failure, are strongly associated with mortality.21,22
Our findings are consistent with previous studies based 
on coronary examinations by CAG or CCTA.7,23 Saely 
et al.23 followed 750 CAG patients and stratified them 
according to presence (≥ 50% stenosis) of CAD and diabe-
tes. After a mean follow-up of 2.2 years, diabetes alone 
was not an independent predictor of vascular events, while 
the risk of vascular events was incrementally higher in 
patients with CAD alone and in patients with both diabetes 
and CAD.23 As in our study, diabetes patients with CAD 
had a longer duration of diabetes than diabetes patients 
without CAD.23 Recently, we used CCTA to examine CAD 
severity in patients with and without diabetes (n = 48,731) 
with a median follow-up of 3.6 years.7 In the absence of 
CAD, diabetes patients had the same low risk of MI as 
non-diabetes patients (adjusted IRR 1.40, 95% CI 
0.71−2.78).7 Hence, the long-term results in this study 
confirm previous shorter term CAG and CCTA studies. 
Table 2. Number of events and risk of myocardial infarction, cardiac death, all-cause death and coronary revascularization in 
patients with and without diabetes stratified by coronary artery disease.
Events  
(n)
Rate per 100 person-
years (95% CI)
CIP  
(95% CI)
Risk differencea 
(95% CI)
Unadjusted HR 
(95% CI)
Adjusted HRb  
(95% CI)
Myocardial infarction
−CAD −DM 
(reference)
795 0.24 (0.22–0.25) 2.55% (2.39–2.74) Reference 1 1
−CAD +DM 128 0.29 (0.24–0.35) 3.15% (2.64–3.72) 0.60 (0.04–1.16) 1.23 (1.02–1.49) 1.202 (0.996–1.451)
+CAD −DM 3957 0.90 (0.87–0.93) 9.33% (9.03–9.59) 6.77 (6.44–7.10) 3.79 (3.51–4.09) 2.75 (2.52–3.01)
+CAD +DM 1055 1.21 (1.14–1.29) 12.29% (11.64–13.03) 9.74 (9.05–10.43) 5.09 (4.64–5.58) 3.79 (3.43–4.20)
Cardiac death
−CAD −DM 
(reference)
689 0.26 (0.24–0.28) 2.51% (2.32–2.70) Reference 1 1
−CAD +DM 126 0.39 (0.33–0.46) 3.57% (3.00–4.25) 1.06 (0.39–1.73) 1.51 (1.25–1.82) 1.65 (1.36–2.00)
+CAD −DM 2768 0.81 (0.78–0.84) 7.41% (7.14–7.69) 4.90 (4.57–5.23) 3.14 (2.88–3.41) 2.36 (2.15–2.60)
+CAD +DM 872 1.40 (1.31–1.50) 11.58% (10.84–12.34) 9.07 (8.33–9.81) 5.42 (4.90–5.99) 4.17 (3.73–4.67)
All-cause death
−CAD −DM 
(reference)
6129 2.29 (2.23–2.35) 22.80% (22.28–23.33) Reference 1 1
−CAD +DM 1117 3.45 (3.25–3.66) 32.63% (30.96–34.36) 9.83 (8.04–11.62) 1.52 (1.43–1.62) 1.67 (1.57–1.78)
+CAD −DM 12,581 3.68 (3.61–3.74) 34.77% (34.25–35.30) 11.97 (11.22–12.72) 1.62 (1.57–1.67) 1.35 (1.30–1.40)
+CAD +DM 3609 5.81 (5.63–6.01) 49.14% (47.89–50.40) 26.34 (25.09–27.59) 2.58 (2.48–2.69) 2.17 (2.08–2.28)
 Unadjusted IRR 
(95% CI)
Adjusted IRRb  
(95% CI)
Coronary revascularization >90 days after index coronary angiography
−CAD −DM 
(reference)
730 0.22 (0.20–0.23) 2.35% (2.18–2.52) Reference 1 1
−CAD +DM 136 0.31 (0.26–0.37) 3.34% (2.82–3.93) 0.99 (0.42–1.57) 1.43 (1.19–1.72) 1.32 (1.09–1.58)
+CAD −DM 7029 1.70 (1.66–1.74) 16.56% (16.21–16.92) 14.21 (13.82–14.60) 7.88 (7.30–8.51) 6.62 (6.03–7.28)
+CAD +DM 1635 2.01 (1.91–2.11) 19.05% (18.22–19.88) 16.70 (15.88–17.52) 9.29 (8.51–10.15) 7.72 (6.95–8.57)
CAD: coronary artery disease; CIP: cumulated incidence proportion; DM: diabetes mellitus; IRR: incidence rate ratio; HR: hazard ratios;  
CI: confidence interval.
aMaximum follow-up of 11 years.
bAdjusted for age, sex, hypertension, active smoking, previous ischemic stroke, peripheral artery disease, procedural priority, year of index coronary 
angiography, statin treatment, oral anticoagulant treatment, and antiplatelet treatment, using patients with neither CAD nor DM as reference.  
IRR was further adjusted for coronary revascularization < 90 days after the index coronary angiography.
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The potential clinical consequence is that screening for 
CAD may be used to differentiate diabetes patients with 
and without increased risk of cardiovascular events and 
guide prophylactic strategies. However, this concept war-
rants validation in prospective randomized trials.
Systematic screening for CAD in asymptomatic diabe-
tes patients is controversial and currently not recom-
mended due to lack of evidence.2,24 Only a single 
randomized clinical trial, the FACTOR 64 trial,25 has 
examined screening for CAD in asymptomatic diabetes 
patients (n = 900) using CCTA. The trial did not find 
screening beneficial in preventing adverse cardiac events 
at 4-year follow-up. However, the trial was limited by a 
lower than anticipated incidence of adverse events. 
Moreover, as randomization was performed before CCTA, 
a potential treatment effect was diluted by the inclusion of 
many low-risk patients. Based on our results, one should 
consider using CCTA for risk stratification followed by 
randomization of high-risk patients with CAD in order to 
avoid dilution of treatment effects. Following the FACTOR 
64 trial, several large randomized control trials have dem-
onstrated reductions in cardiovascular morbidity and 
mortality among patients with type 2 diabetes when treated 
with sodium-glucose cotransporter 2 inhibitors26,27 and 
glucagon-like peptide-1 analogues28,29 in addition to stand-
ard care. The emergence of these cardioprotective glucose-
lowering agents further suggests a need for new prospective 
randomized trials with optimized medical intervention.
The absence of significant CAD appears to be a valid 
predictor of low cardiovascular risk. Though CAG does 
not rule out coronary atherosclerosis, our results confirm 
the usefulness of CAG to predict a low risk of MI for at 
least an 11-year period. A factor that may have contributed 
to the low long-term risk of MI is the high use of prophy-
lactic medications in patients with diabetes. The landmark 
paper by Haffner et al.3 led to an intensified focus on pre-
vention and management of cardiovascular risk factors 
among diabetes patients, including hypertension, dyslipi-
demia and smoking.30 Moreover, improved diabetes detec-
tion may have caused lead time bias and consequently a 
reduced relative risk, when comparing patients with and 
without diabetes. Accordingly, long-term cohort studies 
have demonstrated declining rates of diabetes-related car-
diovascular morbidity and mortality within the last two 
Figure 2. Cumulative incidences of (a) myocardial infarction, (b) cardiac death, (c) all-cause death and (d) coronary 
revascularization in patients with diabetes mellitus (+DM) and without (−DM) diabetes stratified by the presence (+CAD) or 
absence (−CAD) of coronary artery disease.
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decades.31–33 In this study, statin use and anti-hypertensive 
treatment were frequent among diabetes patients with and 
without CAD. This high level of preventive therapy may 
have lowered the diabetes-related risk of MI in our study.
Limitations
First, we did not have access to HbA1c and fasting glucose 
levels to define diabetes or to islet autoantibodies and 
C-peptide levels to classify diabetes type. However, we 
used various registries to minimize the risk of misclassifi-
cation. Second, classification of CAD was based on visual 
angiographic assessment by the treating physician, which 
might have introduced some degree of inter-observer vari-
ation. Using the same classification, we have previously 
been able to identify patients at low-, intermediate- and 
high-cardiovascular risk.34 Another limitation to CAG is 
that the procedure does not describe plaque vulnerability 
and lesion morphology in the vessel wall. Third, asympto-
matic myocardial ischaemia is more frequent in diabetes 
patients and silent MI’s may have lowered the observed 
MI rate in patients with diabetes.35
Conclusion
In conclusion, diabetes patients without CAD by CAG 
have a low risk of MI, not substantially increased com-
pared to patients with neither CAD nor diabetes. In the 
presence of CAD, however, diabetes increases the risk 
of MI.
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